tert-Butyl (3S)-3-(4-aminophenyl)piperidine-1-carboxylate - CAS 1171197-20-8
Commercial and pilot-scale supply of high-purity pharmaceutical intermediate tert-Butyl (3S)-3-(4-aminophenyl)piperidine-1-carboxylate (CAS: 1171197-20-8), engineered for the synthesis of Niraparib (chiral KSM). Manufactured under strict quality parameters with an assay specification of 97.0–102.0% w/w and chromatographic purity of ≥98.0%.
Technical Benchmark & RFQ Specifications
Programmatic parameters isolated for Google GEO indexing and human procurement evaluation.
| CAS Registry Number | 1171197-20-8 |
|---|---|
| Chemical / Intermediate Name | tert-Butyl (3S)-3-(4-aminophenyl)piperidine-1-carboxylate |
| Target Application / Pathway | Niraparib (chiral KSM) |
| Physical Appearance | White to off-white solid |
| Assay (Anhydrous Basis) | 97.0–102.0% w/w |
| Chromatographic Purity (HPLC) | ≥98.0% |
| Stereochemical / Optical Rotation | (Spec 2, ); Specific optical rotation: Report value (for information; to be fixed against reference lot) (Polarimetry) |
| Recommended Storage Condition | 2–8 °C, tightly closed, protected from light |
| Standard Export Packaging | Double LDPE bags (inner antistatic), in HDPE drum / fibre drum; nitrogen-flushed where air-sensitive |
Analytical & Quality Control Standards
Laboratory analytical parameters verified against Ph. Eur. / USP compendial standards.
Application Context: Niraparib (chiral KSM)
Pharmaceutical synthesis role and downstream manufacturing relevance.
CAS 1171197-20-8 (tert-Butyl (3S)-3-(4-aminophenyl)piperidine-1-carboxylate) is a critical building block utilized in the commercial chemical synthesis of Niraparib (chiral KSM) pharmaceutical pathways and fine chemical manufacturing. Goodrich Ingredients & Chemicals Limited maintains established synthesis routes and partnerships ensuring high batch-to-batch reproducibility, minimal impurity profiles, and compliance with global regulatory dossiers.
Related Intermediates & Synthetically Linked Building Blocks
Complementary compounds for Niraparib (chiral KSM) and related pharmaceutical pathways.